SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-21-235079
Filing Date
2021-08-03
Accepted
2021-08-03 17:01:30
Documents
5
Period of Report
2021-08-03
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d193163d8k.htm 8-K 20596
2 EX-3.1 d193163dex31.htm EX-3.1 26544
3 EX-3.2 d193163dex32.htm EX-3.2 174587
4 EX-99.1 d193163dex991.htm EX-99.1 5388
5 GRAPHIC g193163g11l28.jpg GRAPHIC 48746
  Complete submission text file 0001193125-21-235079.txt   295636
Mailing Address 171 OYSTER POINT BLVD., SUITE 500 SOUTH SAN FRANCISCO CA 94080
Business Address 171 OYSTER POINT BLVD., SUITE 500 SOUTH SAN FRANCISCO CA 94080 415-865-2066
Tenaya Therapeutics, Inc. (Filer) CIK: 0001858848 (see all company filings)

IRS No.: 813789973 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40656 | Film No.: 211140769
SIC: 2836 Biological Products, (No Diagnostic Substances)